These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29383624)

  • 41. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria.
    Schwartz CE; Stark RB; Borowiec K; Nolte S; Myren KJ
    Orphanet J Rare Dis; 2021 Sep; 16(1):389. PubMed ID: 34526067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan.
    Usuki K; Ikezoe T; Ishiyama K; Kanda Y; Gotoh A; Hayashi H; Shimono A; Kitajima A; Obara N; Nishimura JI
    Int J Hematol; 2023 Sep; 118(3):311-322. PubMed ID: 37477863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
    Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
    Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.
    Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Ozawa K; Omine M
    Int J Hematol; 2013 Oct; 98(4):406-16. PubMed ID: 23934275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
    de Castro C; Grossi F; Weitz IC; Maciejewski J; Sharma V; Roman E; Brodsky RA; Tan L; Di Casoli C; El Mehdi D; Deschatelets P; Francois C
    Am J Hematol; 2020 Nov; 95(11):1334-1343. PubMed ID: 33464651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry.
    Lee JW; Peffault de Latour R; Brodsky RA; Jang JH; Hill A; Röth A; Schrezenmeier H; Wilson A; Marantz JL; Maciejewski JP
    Am J Hematol; 2019 Jan; 94(1):E37-E41. PubMed ID: 30370949
    [No Abstract]   [Full Text] [Related]  

  • 49. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
    Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
    Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.
    Chonat S; Kulagin A; Maschan A; Bartels M; Buechner J; Punzalan R; Richards M; Ogawa M; Hicks E; Yu J; Baruchel A; Kulasekararaj AG
    Blood Adv; 2024 Jun; 8(11):2813-2824. PubMed ID: 38551806
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study.
    Cella D; Sarda SP; Hsieh R; Fishman J; Hakimi Z; Hoffman K; Al-Adhami M; Nazir J; Cutts K; Lenderking WR
    Ann Hematol; 2022 Sep; 101(9):1905-1914. PubMed ID: 35869984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].
    Ishiyama K; Usuki K; Ikezoe T; Gotoh A; Myren KJ; Tomazos I; Shimono A; Ninomiya H; Sakurai M; Nakao S; Nishimura JI
    Rinsho Ketsueki; 2023; 64(1):9-17. PubMed ID: 36775313
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.
    McKeage K
    Drugs; 2011 Dec; 71(17):2327-45. PubMed ID: 22085388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
    Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
    [No Abstract]   [Full Text] [Related]  

  • 56. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria.
    Seregina EA; Tsvetaeva NV; Nikulina OF; Zapariy AP; Erasov AV; Gribkova IV; Orel EB; Ataullakhanov FI; Balandina AN
    Blood Cells Mol Dis; 2015 Feb; 54(2):144-50. PubMed ID: 25497169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
    Varela JC; Brodsky RA
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
    Zhou S; Dong X; Chen C; Ma L; Wu Y; Zhou Y; Cui Y
    J Pediatr Hematol Oncol; 2021 Aug; 43(6):203-210. PubMed ID: 33902068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go?
    Alashkar F; Dührsen U; Röth A
    Eur J Haematol; 2016 Oct; 97(4):403-5. PubMed ID: 26990688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.
    Kelly RJ; Holt M; Vidler J; Arnold LM; Large J; Forrest B; Barnfield C; Pike A; Griffin M; Munir T; Muus P; Nagumantry SK; Varghese A; Davies JR; Trikha R; Kulasekararaj AG; Mitchell L; Gandhi S
    Blood; 2024 Mar; 143(12):1157-1166. PubMed ID: 38142401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.